Release Date: 2024-06-19

Abiraterone Acetate Treatment in Metastatic Prostate Cancer

Hakan Polat (Author), Yavuz Onur Danacioglu (Author)

Release Date: 2024-06-19

Prostate cancer is the frequently presented malignancy in men, and it is expected that nearly 300,000 people will be diagnosed with it in the United States in 2024. Generally, the five-year survival rate is quite positive at 97.5%, but this rate drops to around 30% in cases with advenced disease. Tumors arise from changes in [...]

Media Type
    Buy from

    Price may vary by retailers

    Work TypeBook Chapter
    Published inCurrent Management of Metastatic Prostate Cancer
    First Page89
    Last Page96
    DOIhttps://doi.org/10.69860/nobel.9786053359142.8
    Page Count8
    Copyright HolderNobel Tıp Kitabevleri
    Licensehttps://nobelpub.com/publish-with-us/copyright-and-licensing

    Prostate cancer is the frequently presented malignancy in men, and it is expected that nearly 300,000 people will be diagnosed with it in the United States in 2024. Generally, the five-year survival rate is quite positive at 97.5%, but this rate drops to around 30% in cases with advenced disease. Tumors arise from changes in the genetic material of the epithelial cells in the prostate gland and typically appear as adenocarcinomas. Adenocarcinoma of the prostate is found within the gland in a multifocal and heterogeneous manner. Metastases of prostate cancer are hormonally sensitive, the primary therapy became aimed at lowering testosterone levels to castration levels through surgical procedures or androgen deprivation therapy (ADT) via gonadotropin-releasing hormone.However, it is rarely used nowadays following the development of more potent and selective androgen synthesis inhibitors. Abiraterone acetate (AA) is a potent and selective inhibitor of cytochrome P17 (CYP17), a key enzyme in androgen synthesis, unlike ketoconazole, which inhibits various cytochrome P pathways. In this section, the effectiveness of Abiraterone Acetate treatment in metastatic prostate cancer aims to be explained, relying on the literature for support.

    Hakan Polat (Author)
    MD, Saglık Bilimleri Universty
    https://orcid.org/0000-0003-1525-1243
    3Hakan Polat has achieved distinguished careers in the clinical and practical medical application of urology, making significant contributions in their field for over 15 years. He hold various academic positions at the University of Health Sciences and works closely with the Faculty of Medicine within the Department of Urology. The international publications of Dr. Polat contribute to the medical literature.

    Yavuz Onur Danacioglu (Author)
    MD, Associate Professor of Urology, Saglık Bilimleri Universty
    https://orcid.org/0000-0002-3170-062X
    3Yavuz Onur Danacıoğlu is also an academic person in the health campus of the largest public university in Turkey. Dr. Danacioglu is involved in both undergraduate teaching of medical students and in the supervision of postgraduate students. He also works as an andrologist and urologist in his clinic. He worked in Weill Cornell Medical College with Prof. Peter N. Schlegel as an observer in 2015. During the progaramme, he observed various male reproductive medicine procedures. He has been a board member of the European Association of Urology since 2018. Besides clinician and research, He is the Editor of Chief of the New Journal of Urology and various advisory editorial board member of many journals.

    • Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26(28):4563- 71.

    • De Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011;364(21):1995- 2005.

    • Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr Rev. 2021;42(3):354-73.

    • Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, et al. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2× 2 factorial design. The Lancet. 2022;399(10336):1695- 707.

    • Watson PA, Arora VK, Sawyers CL. Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nature Reviews Cancer. 2015;15(12):701-11.

    • Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352-60.

    • Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983-92.

    • Hoy SM. Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer. Drugs. 2013;73(18):2077-91.

    • James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338-51.

    • Miller R, Sweeney C. Chemotherapy for metastatic castrate-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2016;19(2):139-44.

    • Pont A. Long-term experience with high dose ketoconazole therapy in patients with stage D2 prostatic carcinoma. J Urol. 1987;137(5):902-4.

    • Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152-60.

    • Cornford P, van den Bergh RC, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II—2020 update: treatment of relapsing and metastatic prostate cancer. Eur Urol.2021;79(2):263-82.

    onix_3.0::thothThoth ONIX 3.0
    onix_3.0::project_museProject MUSE ONIX 3.0
    onix_3.0::oapenOAPEN ONIX 3.0
    onix_3.0::jstorJSTOR ONIX 3.0
    onix_3.0::google_booksGoogle Books ONIX 3.0
    onix_3.0::overdriveOverDrive ONIX 3.0
    onix_2.1::ebsco_hostEBSCO Host ONIX 2.1
    csv::thothThoth CSV
    json::thothThoth JSON
    kbart::oclcOCLC KBART
    bibtex::thothThoth BibTeX
    doideposit::crossrefCrossRef DOI deposit
    onix_2.1::proquest_ebraryProQuest Ebrary ONIX 2.1
    marc21record::thothThoth MARC 21 Record
    marc21markup::thothThoth MARC 21 Markup
    marc21xml::thothThoth MARC 21 XML

    Share This Chapter!